Table 3 Univariate association analysis of MIR34A expression and variant with clinicopathological features.

From: Analysis of microRNA-34a expression profile and rs2666433 variant in colorectal cancer: a pilot study

Characteristics

No. of cases

Fold change

P-value

Genotype

P-value

Mean

AA

AG

GG

Age (years)

 ≤ 55

27 (46.6)

3.14 ± 1.08

0.857

10 (50.0)

12 (48.0)

5 (38.5)

0.795

 > 55

31 (53.4)

3.25 ± 1.15

 

10 (50.0)

13 (52.0)

8 (61.5)

 

Sex

Female

22 (37.9)

3.18 ± 1.22

0.916

8 (40.0)

9 (36.0)

5 (38.5)

0.962

Male

36 (62.1)

3.21 ± 1.05

 

12 (60.0)

16 (6.0)

8 (61.5)

 

Location

Ascending

26 (44.8)

3.03 ± 1.00

0.204

11 (55.0)

9 (3.0)

6 (46.2)

0.797

Transverse

4 (6.9)

3.10 ± 0.92

 

1 (5.0)

(8.0)

1 (7.7)

 

Descending

28 (48.3)

3.37 ± 1.23

 

8 (40.0)

14 (56.)

6 (46.2)

 

Type

Adeno

39 (67.2)

3.14 ± 1.13

0.488

17 (85.0)

16 (64.)

6 (46.2)

0.162

Muci

8 (13.8)

3.63 ± 0.97

 

1 (5.0)

5 (20.0)

2 (15.4)

 

Signet

6 (10.3)

3.16 ± 0.64

 

0 (0.0)

3 (12.0)

3 (23.1)

 

Undif

5 (8.60

2.98 ± 1.66

 

2 (10.0)

1 (4.0)

2 (15.4)

 

Grade

G1

8 (13.8)

3.56 ± 1.10

0.401

3 (15.0)

4 (16.0)

1 (7.7)

0.390

G2

32 (55.2)

3.14 ± 1.15

 

12 (60.0)

15 (60.0)

5 (38.5)

 

G3

18 (31.0)

3.14 ± 1.06

 

5 (25.0)

6 (24.0)

7 (53.8)

 

Tumor size

T1

5 (8.6)

3.70 ± 0.95

0.874

3 (15.0)

2 (8.0)

0 (0.0)

0.518

T2

28 (48.3)

3.12 ± 1.18

 

10 (50.0)

10 (40.0)

8 (61.5)

 

T3

15 (25.9)

3.25 ± 1.13

 

3 (15.0)

8 (32.0)

4 (30.8)

 

T4

10 (17.2)

3.09 ± 1.00

 

4 (20.0)

5 (20.0)

1 (7.7)

 

LN invasion

N0

25 (43.1)

3.36 ± 1.10

0.974

9 (45.0)

10 (40.0)

6 (46.2)

0.761

N1

22 (379)

3.29 ± 0.95

 

9 (45.0)

9 (36.0)

4 (30.8)

 

N2

11 (19.0)

2.67 ± 1.35

 

2 (10.0)

6 (24.0)

3 (23.1)

 

Metastasis

M0

47 (81.0)

3.23 ± 1.09

0.545

17 (85.0)

19 (76.0)

11 (84.6)

0.696

M1

11 (19.0)

3.07 ± 1.24

 

3 (15.0)

6 (24.00

2 (15.4)

 

LVI

No

36 (62.1)

3.12 ± 1.15

0.974

13 (65.0)

17 (68.0)

6 (46.2)

0.398

Yes

22 (37.9)

3.33 ± 1.06

 

7 (35.0)

8 (32.0)

7 (53.8)

 

Dukes*

A

14 (24.1)

3.49 ± 1.21

0.361

6 (30.0)

4 (16.0)

4 (30.8)

0.856

B

9 (15.5)

3.34 ± 0.94

 

2 (10.0)

5 (20.0)

2 (15.4)

 

C

24 (41.4)

3.04 ± 1.07

 

9 (45.)

10 (40.0)

5 (38.5)

 

D

11 (19.0)

3.07 ± 1.24

 

3 (15.0)

6 (24.0)

2 (15.4)

 

Relapse

No

37 (64.9)

3.34 ± 1.01

0.803

15 (75.0)

12 (50.0)

10 (76.9)

0.131

Yes

20 (35.1)

2.96 ± 1.28

 

5 (25.0)

12 (50.0)

3 (23.1)

 

Died

No

18 (32.1)

3.18 ± 1.15

0.682

3 (15.0)

9 (39.1)

6 (46.2)

0.112

Yes

38 (67.9)

3.22 ± 1.13

 

17 (85.0)

14 (60.9)

7 (53.8)

 

DFS (months)

Mean

58 (100)

43.0 ± 11.8

 

45.40 ± 9.27

43.48 ± 14.36

38.46 ± 9.40

0.256

OS (months)

Mean

58 (100)

47.7 ± 11.6

 

49.25 ± 9.37

48.96 ± 14.57

43.15 ± 7.46

0.276

  1. Data are shown as mean ± standard deviation or frequency as number (percentage). Chi-square, student's t, ANOVA tests were used.
  2. Adeno adenocarcinoma; Muci Mucinous carcinoma; Signet Signet ring carcinoma; Undif Undifferentiated carcinoma; LN lymph node; LVI lymphovascular invasion; DFS disease-free survival; OS overall survival.
  3. *Tumors were staged clinically according to the TNM classification.
Back to article page